Global High-Priority Regulatory Events — April 09, 2026

09-04-2026

Kallam Textiles Limited's insolvency application filed by Union Bank of India under Section 7 of the Insolvency and Bankruptcy Code, 2016 (case CP (IB)/3/7/AMR/2026) was admitted by the National Company Law Tribunal, Amaravati Bench, via order dated April 6, 2026. Mr. Chillale Rajesh (IBBI/IPA-001/IP-P00699/2017-2018/11226) has been appointed as the Interim Resolution Professional to oversee the Corporate Insolvency Resolution Process (CIRP). This development signals severe financial distress for the company, with no operational or financial metrics disclosed.

• ·NCLT case reference: CP (IB)/3/7/AMR/2026
• ·IRP registration: IBBI/IPA-001/IP-P00699/2017-2018/11226
• ·Prior corporate announcement reference: dated April 7, 2026 under Regulation 30 of SEBI (LODR)

09-04-2026

Vas Infrastructure Limited, under Corporate Insolvency Resolution Process (CIRP), has rescheduled its 24th Committee of Creditors (CoC) meeting from Tuesday, April 14, 2026, to Wednesday, April 15, 2026. This update follows an earlier intimation dated April 08, 2026, and complies with Regulation 30 of SEBI (LODR) Regulations, 2015. No other changes or outcomes from the meeting were disclosed.

• ·CIN: L65100MH1994PLC076538
• ·IBBI Reg. No. IBBI/IPA-002/IP-N000932/2019-20/12973, valid upto 31.12.2026
• ·Resolution Professional address: Flat No. B 703/704, Seventh Floor, River Park CHS Ltd., Dattani Park Road, Thakur Village, Kandivali (East), Mumbai - 400101
• ·Email: cirp@vasinfra.com
• ·Scrip No.: 531574

09-04-2026

Mahindra & Mahindra Ltd approved acquisition of 26% equity stake in step-down subsidiary Neon Hybren Private Limited for up to ₹11.17 Cr in one or more tranches, via Share Subscription and Shareholders Agreement executed on April 9, 2026, to comply with Electricity Rules 2005 for a 30 MW AC Group Captive Solar Power Plant in Punjab. Neon, involved in power generation and renewable energy, reported Nil revenue from operations, a PAT loss of (9.23) Lakhs, and Net Worth of 10.77 Lakhs for FY25 ended March 31, 2025. Post-transaction, MSPL's stake dilutes to 74% from 100%, with completion targeted by December 31, 2026.

• ·Neon incorporated on 3rd May 2024
• ·Transaction approved on 9th April 2026 at 12:08 p.m.
• ·Indicative completion timeframe: 31st December 2026
• ·Neon FY24 and FY23 turnover: Not Applicable

09-04-2026

Shalibhadra Finance Limited has received NSE approval for listing 30888400 fully paid-up equity shares of face value Rs. 10 each, effective April 10, 2026, under symbol SAHLIBHFI, enhancing visibility and liquidity alongside its existing BSE listing (Scrip Code: 511754). The NBFC, focused on rural/semi-urban retail financing with AUM of about Rs. 200 crores, over 60 branches, and 1+ Lac active customers, views this as a major milestone for capital market engagement. No declines or flat metrics reported in this listing announcement.

• ·Face value of equity shares: Rs. 10 each
• ·BSE Scrip Code: 511754
• ·NSE Symbol: SAHLIBHFI; Series: EQ
• ·Certain shares under lock-in up to 15-May-2026 (e.g., 17000 shares from 7144001-7161000)
• ·CIN: L65923MH1992PLC064886
• ·Company is a retail-focused NBFC catering to rural and semi-urban segments

09-04-2026

09-04-2026

Pricol Limited has categorically denied rumors circulating on social media (from handles like @REDBOXINDIA on X) claiming the acquisition of a 100% stake in a German automotive components firm. The company confirms the information is factually incorrect, baseless, and misleading, with no announcement, agreement, or arrangement made. Investors are advised to rely solely on official BSE/NSE filings and the company's website for authentic information.

• ·Filing reference: PL/SEC/TGT/2026-2027/008
• ·Scrip codes: PRICOLLTD (NSE), 540293 (BSE)
• ·Compliance cited: Regulation 30(11) of SEBI (LODR) Regulations, 2015

09-04-2026

Pradeep Metals Limited (PML) disclosed receiving an NCLT Mumbai Bench order dated April 8, 2026, directing it to convene a meeting of equity shareholders via video conferencing, audio-visual means, or physical presence to consider and approve the Scheme of Amalgamation with Nami Capital Private Limited (NCPL). This follows PML and NCPL board approvals on March 3, 2025, and BSE's observation letter with no adverse comments dated July 15, 2025. PML will announce the meeting date and submit the detailed notice and explanatory statement in due course.

• ·NCPL engaged in trading steel metals and investing in quoted/unquoted securities.
• ·PML engaged in manufacturing metal forgings, castings, automotive parts, and defence/non-defence systems.
• ·Scrip Code: 513532
• ·NCLT Case: C.A.(CAA)/213(MB)/2025
• ·PML website for scheme: https://www.pradeepmetals.com/scheme-of-amalgamations/

09-04-2026

Tulive Developers Limited submitted to BSE the reasoned recommendations of its Committee of Independent Directors (IDC), approved at their meeting on April 08, 2026, regarding the proposed voluntary delisting offer to public shareholders under SEBI Delisting Regulations, 2021. The recommendations, along with voting pattern details, were published in Financial Express (English, all editions), Janasatta (Hindi, all editions), and Navshakti (Marathi, Mumbai edition), and forwarded to Saffron Capital Advisors Private Limited, the delisting offer manager. The document is available on the company's website www.tulivedevelopers.com.

• ·BSE Scrip Code: 505285
• ·Recommendation made pursuant to Regulation 28 of SEBI (Delisting of Equity Shares) Regulations, 2021

09-04-2026

Zenrock Chemicals Private Limited (Acquirer) along with PACs—India Special Assets Fund III (PAC 1), ISAF III Onshore Fund (PAC 2), and Special Situation India Fund (PAC 3)—has published the Offer Opening Public Announcement cum Corrigendum on April 09, 2026, in Financial Express (English All Edition), Jansatta (Hindi All Edition), and Navshakti (Marathi Mumbai Edition) for an open offer to public shareholders of Indo Borax & Chemicals Limited pursuant to SEBI (SAST) Regulations. The tendering period commences on April 10, 2026. This follows prior submissions: Public Announcement on December 15, 2025; Detailed Public Statement on December 22, 2025; Draft Letter of Offer on December 30, 2025; and Letter of Offer on April 02, 2026.

• ·Publication newspapers: Financial Express (English All Edition), Jansatta (Hindi All Edition), Navshakti (Marathi Mumbai Edition)
• ·Contact details: Yogesh Malpani (+91 89767 58023, yogesh.malpani@iiflcap.com); Dhruv Bhavsar (+91 79779 58803, dhruv.bhavsar@iiflcap.com); Jesica Thakkar (+91 98195 07872, jesica.thakkar@iiflcap.com)

09-04-2026

Solid Power, Inc.'s 2026 proxy statement outlines the virtual annual meeting on May 20, 2026 at 10:00 a.m. MT for record holders as of March 23, 2026, seeking votes to elect three Class II director nominees, ratify Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026, and approve by non-binding advisory vote the compensation of named executive officers, with the Board recommending FOR all proposals. The Board held 6 meetings in 2025 with all directors except Dr. Feurer attending at least 75% of meetings and committees; it features a classified structure with staggered terms and majority independent directors led by Chairperson MaryAnn Wright. Committees met 4-5 times each in 2025, overseeing audit, governance/ESG, compensation, and risks including cybersecurity.

• ·Board has three standing committees: Audit (financial reporting, internal controls, cybersecurity), Governance and Corporate Responsibility (director nominations, ESG, independence), Human Resources and Compensation (executive pay, succession planning).
• ·All directors except Dr. Feurer and Mr. Van Scoter determined independent under Nasdaq and SEC rules.
• ·Classified board: Class I terms expire 2028, Class II 2026 (election at meeting), Class III 2027.
• ·Cybersecurity oversight by Audit Committee with annual reviews and third-party assessments.
• ·Annual Board and committee self-evaluations overseen by Governance Committee.

09-04-2026

Piper Sandler Companies reported strong 2025 fiscal year performance with adjusted net revenues of $1.88B (second-highest ever), adjusted net income of $318M reflecting a 39% increase from 2024, and adjusted EPS of $4.43, driven by contributions across its diversified platform and expense discipline. The Board nominated ten directors for election at the 2026 annual meeting, including eight independent directors and a new nominee Stuart M. Essig; all per-share amounts retroactively adjusted for a four-for-one stock split on March 23, 2026. No declines or flat metrics were reported.

• ·All per share and share amounts retroactively adjusted for four-for-one forward stock split completed March 23, 2026.
• ·Stuart M. Essig appointed effective February 4, 2026, recommended by CEO; first time standing for shareholder election.
• ·Eight of ten director nominees are independent under NYSE rules.
• ·Adjusted figures are non-GAAP measures; reconciliations in Appendix A.

09-04-2026

Einride AB filed a Rule 425 under the Securities Act of 1933 (deemed filed under Rule 14a-12 of the Exchange Act) on April 9, 2026, disclosing an investor presentation made available on April 8, 2026, regarding a proposed business combination with Legato Merger Corp. III (Commission File No. 001-41945). The presentation is strictly for informational purposes, not constituting an offer, solicitation, or recommendation, and is laden with extensive disclaimers on forward-looking statements, risks, and lack of warranties. No financial metrics, transaction terms, or performance data are included.

• ·Subject Company: Legato Merger Corp. III, Commission File No.: 001-41945
• ·References Legato's prospectus dated February 5, 2024, filed with SEC on February 6, 2024

09-04-2026

Beyond Meat's 2025 net revenues declined 15.6% YoY to $275,496 thousand from $326,452 thousand, with all segments contracting: U.S. Retail -17.5%, U.S. Foodservice -18.1%, International Retail -11.1%, and International Foodservice -13.7%. Gross profit plummeted 81.7% to $7,646 thousand (2.8% margin vs. 12.8% prior year) despite a 5.9% COGS reduction to $267,850 thousand, while operating loss widened to $(333,621) thousand from $(156,124) thousand amid $48,987 thousand asset write-down and $51,288 thousand impairments. Total non-cash charges reached $62,766 thousand, including costs from China operations cessation.

• ·Inventory write-offs: $260 thousand
• ·Accelerated depreciation in COGS: $5,575 thousand; in R&D: $915 thousand
• ·SG&A loss on write-down and write-off of assets: $3,712 thousand
• ·Incremental excess and obsolescence provision: $6,672 thousand
• ·Expenses related to cessation of operational activities in China (COGS): $5,835 thousand; (operating expenses): $1,272 thousand
• ·R&D expenses: 8.4% of revenues (down from 8.6%)
• ·SG&A expenses increased to 79.0% of revenues from 52.0%

09-04-2026

AMASS Brands filed an S-1 registration statement on April 8, 2026, for a direct listing/IPO, disclosing board committee structures, code of conduct, and executive compensation for fiscal years 2024 and 2025. Named executive officer total compensation showed mixed results: CEO Mark T. Lynn's salary increased ~20% to $200,600 with flat total comp, COO Erin K. Green's total rose significantly to $1,192,600 driven by $992,000 in options (salary flat at ~$200,600), while no bonuses were paid to any NEOs and former interim CFO Geoffrey McFarlane's pay declined slightly to $240,000. The company plans post-listing compensation adjustments and equity grants under the 2016 Stock Option Plan.

• ·No employer matching or nonelective contributions to 401(k) Plan in FY2024 or FY2025.
• ·All committee members (Audit, Compensation, Nominating) determined independent per Nasdaq and SEC rules.
• ·Zach Ament eligible for pro-rata $40,000 bonus upon direct listing closing.

09-04-2026

Paloma Acquisition Corp I announced on April 8, 2026, that holders of its IPO units (PALOU) may elect to separate and trade the underlying Class A ordinary shares (PALO) and redeemable warrants (PALOW) starting April 13, 2026. Each unit consists of one Class A ordinary share (par value $0.0001) and one-half of one redeemable warrant, with each whole warrant exercisable for one Class A share at $11.50 per share. Unseparated units will continue trading on Nasdaq under PALOU, and brokers must contact transfer agent Efficiency INC for separation.

• ·Filing submitted on behalf of Paloma Acquisition Corp I, a Cayman Islands incorporated emerging growth company trading on Nasdaq.

09-04-2026

ARC Group Acquisition I Corp. (ARCL) filed an S-1/A amendment to its registration statement on April 9, 2026, detailing SPAC-related securities such as private units, Class B ordinary shares, founder shares, and representative shares involving the Sponsor, Mfh2 LLC, and Ian Hanna. The filing outlines multiple hypothetical scenarios for over-allotment option exercise (none to full) and public shareholder redemptions (0% to 100% of maximum) as of December 31, 2025, including impacts on net proceeds, tangible book value, and shares outstanding. The offering price is set at $10.00 per unit.

• ·Scenarios include no/full over-allotment with redemptions at 25%, 50%, 75%, or 100% of maximum.
• ·Key dates: April 8, 2026 (Sponsor private units and shares); May 27, 2025 (Class B shares to Sponsor); December 31, 2025 (various redemption and dilution calculations).

09-04-2026

RMX Industries, Inc. (formerly Reticulate Micro, Inc., name changed March 23, 2023) filed an S-1 registration statement on April 9, 2026, to register securities under the 1933 Act, signaling preparation for an initial public offering. The filing incorporates by reference over 70 exhibits, including private placement subscription agreements and promissory notes from 2022 to 2026, multiple executive employment, consulting, and separation agreements, IP licenses and purchases, leases, joint ventures, escrow agreements, and amendments to the 2022 Equity Incentive Plan. No financial performance metrics, period-over-period comparisons, or specific monetary amounts are detailed in the provided filing content.

• ·Incorporated in Nevada (EIN: 882960484)
• ·Fiscal year end: December 31
• ·Business address: 4514 Cole Ave, Ste. 600, Dallas, TX 75205
• ·SIC: 7370 (Services-Computer Programming, Data Processing, etc.)
• ·SEC file number: 333-294940

09-04-2026

The proxy statement discloses material weaknesses in Boost Run's internal control over financial reporting, including inadequate IT general controls, insufficient segregation of duties, and lack of qualified personnel, which remain unremediated despite some remedial actions as of December 31, 2025. Management expects remediation efforts, such as implementing an enhanced ITGC framework and hiring additional expertise, to continue into 2026, with full compliance testing potentially extending further. Additional risks include dependence on key management personnel, competitive hiring challenges, and evolving regulations on AI, machine learning, cloud services, and export controls on AI-related technologies like GPUs.

• ·Boost Run not required to evaluate internal controls prior to Prospectus but identified material weaknesses during preparation.
• ·Remediation testing expected to extend into 2026; Section 404 reporting begins with 10-K for year ending December 31, 2026.
• ·EU AI Act entered force August 1, 2024, with majority requirements applying from 2026; fines up to 7% of worldwide annual turnover.
• ·U.S. export controls on AI chips updated October 2022, October 2023, January 2025 (later rescinded but modified).

09-04-2026

Resources Connection, Inc. reported Q3 FY2026 revenue of $107.9M, down 16.6% YoY from $129.4M, and nine-month revenue of $345.9M, down 16.0% YoY from $412.0M, reflecting declines in billings. However, net loss narrowed significantly to $9.5M in Q3 (from $44.1M YoY) and $24.5M for nine months (from $118.5M YoY), driven by absence of prior-year goodwill impairment charges ($42.0M Q3, $125.4M nine months) and lower SG&A expenses.

• ·Cash and cash equivalents decreased to $82.8M from $86.1M at fiscal year-end.
• ·Accrued salaries and related obligations declined to $32.7M from $47.9M.
• ·Cash dividends declared per share reduced to $0.07 in Q3 (from $0.14 YoY) and $0.21 for nine months (from $0.42 YoY).
• ·Weighted-average basic shares outstanding: 33,698 (Q3 FY2026) vs 32,938 (Q3 FY2025).

09-04-2026

Webull Corp's 20-F annual report discloses significant revenue concentration risk from a limited number of market makers and liquidity providers, with top contributors shifting between 2024 (e.g., DASH at 18.5%, Susquehanna at 11.2%) and 2025 (e.g., DASH declining to 13.2%, Susquehanna to 4.0%, while Citadel rose to 11.7% and Jane Street at 11.5%). While customer retention remains strong at 97% in Q4 2025, risks include potential dilution and price volatility from resales of Webull Class A Ordinary Shares and warrant exercises.

• ·Registered users are those who have registered on the platform but not necessarily opened a brokerage account.
• ·Funded accounts are brokerage accounts with initial deposit where balance has not dropped to or below zero for 45 consecutive days.

09-04-2026

Alchemy Investments Acquisition Corp 1's 10-K filing highlights risks associated with its SPAC structure, including obligations to repay or issue shares for up to $1,500,000 in potential working capital loans from its sponsor, officers, directors, or affiliates. It also discloses risks of change in control from substantial Ordinary Share issuances, cash flow diversion to debt servicing limiting funds for dividends and other purposes, and borrowing limitations compared to less-leveraged competitors. Additionally, issuing equity below $10.00 per share or certain transfer arrangements could trigger upward adjustments to warrant exercise prices, potentially complicating the initial business combination.

• ·Warrant exercise price adjusts to 115% of the greater of (x) 20-out-of-30 day VWAP starting 150 days post-business combination or (y) $3.00, capped at $11.50, if equity issued below $10.00 minimum issue price.
• ·$18.00 per share warrant redemption trigger adjusts to adjusted exercise price plus $6.50 under the same conditions.

09-04-2026

For the year ended December 31, 2025, Healthy Extracts Inc. reported revenue growth of 45% YoY to $4,511,997 and gross profit increase of 27% to $2,422,491, supported by the acquisition of Gummy USA LLC which drove total assets to $27,824,664 from $2,377,973. However, general and administrative expenses surged 61% to $3,366,341, leading to a widened net loss of $881,119 from $840,671 in 2024, while current assets declined to $1,327,317.

• ·Net cash provided by operating activities decreased to $165,520 from $281,968 YoY.
• ·Cash flows from investing activities provided $56,301, including acquisition of Gummy USA LLC.
• ·Weighted average shares outstanding increased to 9,305,121 from 2,978,540, with basic and diluted loss per share improving to $(0.09) from $(0.28).
• ·Raw materials inventory decreased to $534,514 from $1,932,383.

09-04-2026

Wabash National Corporation announced the transition of Michael N. Pettit from Senior Vice President, Chief Growth Officer to a non-executive Senior Advisor role effective April 8, 2026, with his employment continuing until the third quarter of 2026 to ensure a smooth handover. During this transition period, Pettit will receive continued annual base salary at $575,000, pro-rated 2026 incentive bonus eligibility, and vesting of existing equity awards, but no new grants. Upon separation, he will be eligible for severance under the Executive Severance Plan, subject to release of claims and covenant compliance.

• ·Transition Date: April 8, 2026
• ·Separation Date: Third quarter of 2026
• ·Pettit reports to Chief Executive Officer or designee as Senior Advisor
• ·No participation in Change in Control Plan post-Transition Date

09-04-2026

Abra Financial Holdings, Inc.'s CEO Bill Barhydt appeared on Yahoo Finance TV on April 8, 2026, discussing the $750 million SPAC merger with New Providence Acquisition Corp. III (announced via Business Combination Agreement dated March 16, 2026) to list on NASDAQ under ticker ABRX, highlighting benefits like building trust as a public RIA and advancing asset tokenization and DeFi lending. He expressed bullish views on Bitcoin, citing rising global liquidity and a 65% chance of reaching all-time highs near $100K by year-end. The filing includes standard forward-looking disclaimers and risks such as transaction failure or shareholder approval issues.

• ·Business Combination Agreement dated March 16, 2026
• ·Interview aired April 8, 2026 at 4:30 pm ET
• ·Bitcoin current price referenced as $71,000 during interview
• ·Post-merger NASDAQ ticker: ABRX
• ·Upcoming SEC Form S-4 Registration Statement including proxy statement/prospectus

09-04-2026

Petrobras filed its 20-F annual report on April 09, 2026, providing definitions for key terms and operational data as of December 31, 2025. Total gross productive oil wells stood at 846 (net 728.09), and natural gas wells at 259 (net 141.13), predominantly in Brazil consolidated subsidiaries. Total gross developed acreage was 3,086,523 acres (net 2,605,325), with undeveloped gross at 945,532 acres (net 624,811); D&M audited 93.6% of Brazil proved reserves, equating to 93.2% company-wide.

• ·Gaspetro divested in July 2022; Petrobras previously held 51% equity interest.
• ·Productive wells in Brazil consolidated: oil gross 770/net 716, gas gross 88/net 84.
• ·Reserves estimated per SEC regulations using 12-month average prices; also per ANP/SPE due to Brazilian rules.

09-04-2026

New Providence Acquisition Corp. III filed a Form 425 disclosing a Yahoo Finance TV interview with Abra Financial Holdings, Inc. CEO Bill Barhydt on April 8, 2026, discussing the $750 million SPAC business combination announced March 16, 2026, to list Abra on NASDAQ under ticker ABRX. Barhydt expressed optimism on Bitcoin's potential to hit all-time highs amid rising global liquidity, while highlighting Abra's DeFi lending advantages over private credit, noting past counterparty risks in centralized lending have been mitigated. The filing includes standard forward-looking statement disclaimers and risks related to the merger completion.

• ·Business Combination Agreement dated March 16, 2026, between Abra Financial Holdings, Inc., New Providence Acquisition Corp. III, and Aether Merger Sub I, Corp.
• ·Upcoming Registration Statement on Form S-4 with definitive proxy statement/prospectus.
• ·Post-merger ticker: ABRX on NASDAQ.
• ·Abra operates as a registered investment advisor (RIA).

09-04-2026

Amazon.com, Inc.'s 2026 Proxy Statement solicits votes for the election of 11 director nominees at the virtual Annual Meeting of Shareholders on May 20, 2026, at 9:00 a.m. Pacific Time, following Keith B. Alexander's announcement on April 7, 2026, that he will not stand for re-election. The Board emphasizes a balanced composition with diverse skills, qualifications, and tenures to support long-term performance, oversight of sustainability, governance, and risks. No financial results or period-over-period comparisons are provided.

• ·Proxy materials first made available to shareholders on or about April 9, 2026.
• ·Principal offices: 410 Terry Avenue North, Seattle, Washington 98109.
• ·Voting methods: Internet (www.proxyvote.com), QR code, telephone (800-690-6903).
• ·Board committees mentioned: Leadership Development and Compensation (Chair: Edith W. Cooper), Nominating and Corporate Governance (Jamie S. Gorelick).

09-04-2026

OptimizeRx Corp. (Nasdaq: OPRX) announced the appointment of Mary Varghese Presti, Corporate Vice President and Chief Operating Officer of Microsoft’s Health & Life Sciences organization, as an independent director to its Board of Directors on April 8, 2026. This appointment supports the company's ongoing board refresh and expansion, bringing her over 25 years of expertise in healthcare, life sciences, technology scaling, AI integration, M&A, and operational efficiency from roles at Microsoft, Nuance, IBM Watson Health, athenahealth, and Pfizer. CEO Steve Silvestro highlighted her alignment with OptimizeRx's strategy to evolve into an integrated, product-led platform with growing recurring revenue.

• ·Varghese Presti involved in Microsoft’s Nuance acquisition integration and IBM Watson Health divestiture diligence.
• ·OptimizeRx headquartered in Waltham, Massachusetts.
• ·Investor Relations contact: Andy D’Silva (adsilva@optimizerx.com); Marketing: Jennifer Dinkel (jdinkel@optimizerx.com); Press: optimizerx@matternow.com.

09-04-2026

Live Ventures Incorporated's indirect wholly-owned subsidiary, Vintage Stock Inc., amended the Employment Agreement with its President and CEO, Rodney Spriggs, effective March 31, 2026, extending the term to March 31, 2028. The Third Amendment includes a one-time cash bonus of $250,000 payable on or before April 14, 2026, and an additional 80 hours of paid time off per calendar year.

• ·Third Amendment approved by Compensation Committee via written consent
• ·Third Amendment filed as Exhibit 10.145

09-04-2026

Ellington Financial Inc. will hold its 2026 Annual Meeting of Stockholders virtually on May 28, 2026, at 10:30 a.m. ET to elect five directors to serve until the 2027 annual meeting, conduct an advisory vote on executive compensation, ratify PricewaterhouseCoopers LLP as independent auditor for the year ending December 31, 2026, and approve the 2026 Equity Incentive Plan. As of the record date of March 31, 2026, there were 124,649,023 Common Shares outstanding, entitling holders to one vote per share. Proxies must be received by May 13, 2026, and a majority of votes constitutes a quorum.

• ·Annual Meeting conducted virtually only via www.virtualshareholdermeeting.com/EFC2026; 16-digit control number required for access and voting during meeting.
• ·Election of directors, advisory vote on executive compensation, and approval of 2026 Equity Incentive Plan are non-routine matters requiring specific broker instructions to avoid broker non-votes.
• ·Auditor ratification is a routine matter allowing broker discretionary voting.

09-04-2026

Wipro Limited has notified stock exchanges that its Board of Directors will consider a proposal for buyback of equity shares, along with necessary incidental matters, at the meeting scheduled for April 15-16, 2026. The intimation is issued pursuant to Regulation 29(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The outcome of the meeting will be communicated to the exchanges shortly after its conclusion on April 16, 2026.

• ·Compliance with Companies Act, 2013; SEBI (Buy-Back of Securities) Regulations, 2018; and other applicable laws.
• ·Stock symbols: BSE: 507685, NSE: WIPRO, NYSE: WIT.

09-04-2026

Forte Biosciences, Inc. (Nasdaq: FBRX) announced the pricing of a $150 million public offering of 5,709,936 shares of common stock at $26.27 per share, with underwriters granted a 30-day option to purchase up to 856,490 additional shares. Gross proceeds are expected to be approximately $150 million before deducting underwriting discounts, commissions, and other expenses, to be used for working capital, funding clinical development of FB102, and other research activities. The offering is expected to close on or about April 10, 2026, subject to customary conditions.

• ·Guggenheim Securities and Barclays acting as joint book-running managers.
• ·Offering pursuant to Registration Statement on Form S-3 (File No. 333-286226).
• ·Intended use of net proceeds includes working capital and general corporate purposes.

09-04-2026

Whitestone REIT (NYSE: WSR) has entered a definitive merger agreement to be acquired by Ares Real Estate funds for $1.7 billion in an all-cash deal at $19.00 per common share and operating partnership unit, representing a 12.2% premium to the April 8, 2026 closing price and 26.5% to the unaffected price prior to the March 5, 2026 Reuters article. The portfolio includes 56 convenience-focused retail properties totaling 4.9 million square feet in high-growth markets like Phoenix, Austin, Dallas-Fort Worth, Houston, and San Antonio, with the deal unanimously approved by Whitestone's Board and expected to close in Q3 2026 subject to shareholder approval and customary conditions. While delivering immediate value to shareholders, the transaction carries standard risks including potential failure to close, business disruptions, and litigation.

• ·Transaction unanimously approved by Whitestone Board of Trustees; not subject to financing condition.
• ·Upon closing, Whitestone will become private and delist from NYSE.
• ·Advisors: BofA Securities and Jones Lang LaSalle Securities (financial for Whitestone); Citigroup and Morgan Stanley (financial for Ares); Bass Berry & Sims (legal for Whitestone); Kirkland & Ellis (legal for Ares).

09-04-2026

ReserveOne Holdings, Inc. (Pubco), a wholly-owned subsidiary of ReserveOne, Inc., filed a Form 425 disclosing communications related to its proposed business combination with M3-Brigade Acquisition V Corp., initially agreed on July 7, 2025. CEO Jaime Leverton shared optimistic messages on LinkedIn and X about building a new digital asset company and published an article in the Milken Institute’s 2026 Power of Ideas series emphasizing internal trust-building. However, the filing heavily cautions on forward-looking statements, highlighting substantial risks including failure to complete the merger, high crypto volatility, regulatory uncertainties, lack of operating history, and potential high redemptions by M3-Brigade shareholders.

• ·Business Combination Agreement entered into on July 7, 2025
• ·Communications posted on LinkedIn and X on April 8, 2026
• ·Registration Statement on Form S-4 filed with SEC, including preliminary proxy statement/prospectus
• ·Risks include lack of operating history, potential shareholder redemptions, listing failure post-merger, and crypto price volatility

09-04-2026

Tata Consultancy Services Limited's Board approved the audited standalone and consolidated financial results for the year ended March 31, 2026, under Indian Accounting Standards, with an unmodified opinion from statutory auditors B S R & Co. LLP. The Board recommended a final dividend of ₹31 per equity share of ₹1 each, payable after the 31st Annual General Meeting subject to shareholder approval. No comparative financial metrics or performance details were disclosed in the filing.

• ·Audited results cover the Group including 57 subsidiaries listed in Annexure I, with recent additions such as TRIL Bengaluru Real Estate Five Limited and Six Limited (acquired Jan 29, 2025), HyperVault AI Data Center Limited (incorporated Oct 29, 2025), and others.
• ·Quarter ended March 31, 2026 results derived as balancing figure between full FY audited and prior published Q3 figures.

09-04-2026

Pampa Energía Inc.'s 20-F annual report, filed April 09, 2026, outlines key risk factors including deteriorating economic, business, social, and political conditions in Argentina such as high inflation, peso exchange rate fluctuations, and their impact on costs. It highlights risks from government interventions affecting taxes, tariffs, regulations, environmental matters, and delays in approvals, alongside uncertainties in future government actions on tariffs and stricter peso-to-foreign currency exchange restrictions. Additional risks include international geopolitical developments and failures in governmental approvals for proposed measures.

09-04-2026

SUNation Energy, Inc. entered into a Sales Agreement with Maxim Group, LLC on April 8, 2026, authorizing an at-the-market offering of up to $3,599,586 of its common stock (par value $0.05 per share) pursuant to an effective Form S-3 registration statement (File No. 333-286663). The Sales Agent will receive a commission of up to 3.0% of gross proceeds and reimbursement for legal fees up to $50,000, with sales made using commercially reasonable efforts but no obligation to sell any shares. The agreement includes customary representations, warranties, covenants, and indemnification provisions.

• ·Registration Statement on Form S-3 (File No. 333-286663) declared effective April 29, 2025
• ·Sales Agreement filed as Exhibit 10.1; Legal opinion of Rimon P.C. as Exhibit 5.1
• ·Agreement dated April 8, 2026; 8-K filed April 9, 2026

09-04-2026

Universal Health Services Inc.'s 2026 DEF 14A Proxy Statement highlights 2025 quality and patient care achievements across acute care (including $3.9B in uncompensated care, 18 hospitals earning A/B safety grades from Leapfrog, and nearly 60 High Performing awards from U.S. News) and behavioral health (exceeding national averages in 8/11 CMS measures, 4.4/5 patient satisfaction, 83% showing meaningful improvement). The filing details the executive team led by Marc D. Miller (CEO/President) and Alan B. Miller (Executive Chairman), and outlines a performance-aligned compensation philosophy emphasizing stockholder value without noted shortfalls or declines.

• ·Behavioral health NPS scores in 2025: aggregate 45.0 (high), outpatient 63.5 (excellent), Patriot Support Programs 55.5.
• ·Patient satisfaction in behavioral health: 4.4 out of 5 overall care; referral sources: 4.3/5 average, 4.4/5 quality of care.
• ·Exceeded national average in 8 out of 11 CMS Inpatient Psychiatric Facility Quality Reporting measures in 2025.

09-04-2026

Bhogilal Family Trust submitted a compliance status certificate from an independent auditor to BSE Limited, confirming adherence to the SEBI exemption granted on July 5, 2018 (ref: WTM/GM/CFD/34/2018-19) for the off-market inter se transfer of 25,00,000 (8.7060%) shares of Batliboi Ltd from Mr. Nirmal Bhogilal to the Trust. The certificate pertains to Regulation 11(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. No financial performance metrics or period-over-period changes are reported.

• ·Exemption dated July 5, 2018; reference no. WTM/GM/CFD/34/2018-19
• ·Letter dated April 09, 2026
• ·Address: 5th Floor, Bharat House, 104, Mumbai Samachar Marg, Fort, Mumbai-400001

09-04-2026

Avanti Feeds Limited has published newspaper notices informing shareholders about the second 'Saksham Niveshak' 100 days Campaign, initiated by IEPFA, running from April 01, 2026, to July 09, 2026, to claim unpaid dividends before transfer to the Investor Education and Protection Fund. Shareholders are urged to update KYC details including PAN, bank accounts, and nominee information using forms ISR-1, ISR-2, and SH-13 via the company's website or registrar KFin Technologies Ltd. The notices were published in Financial Express and Andhra Prabha on April 09, 2026, and are available on www.avantifeeds.com.

• ·IEPFA mail dated March 27, 2026, prompted the notice.
• ·Forms required: ISR-1 (with self-attested KYC), ISR-2 (with bank attestation or cancelled cheque), SH-13 (for nominee details).
• ·Registrar contact: KFin Technologies Ltd., Selenium Tower B, Financial District, Nanakramguda, Hyderabad-500032; email: einward.ris@kfintech.com; Toll Free: 1-800-309-4001.
• ·Deadline for claims: July 09, 2026.

09-04-2026

Mereo BioPharma Group plc has issued its DEF 14A proxy statement for the 2026 Annual General Meeting on May 14, 2026, at 2:00 p.m. BST (9:00 a.m. ET) in London, seeking shareholder approval for 11 resolutions including adoption of the 2025 annual accounts, re-appointment of PricewaterhouseCoopers LLP as auditors, approval of directors' remuneration report and policy, advisory approval of named executive officer compensation, re-election of directors Justin Roberts, Dr. Daniel Shames, and Marc Yoskowitz, and renewal of authorities to allot shares up to a maximum aggregate nominal amount of £3,591,354.73 expiring June 30, 2029. The Board unanimously recommends voting FOR all resolutions. No financial performance data or period-over-period comparisons are provided in the filing.

• ·Proxy appointment deadline for ordinary shares: 2:00 p.m. BST (9:00 a.m. ET) on May 12, 2026.
• ·ADS proxy cards deadline: 10:00 a.m. ET (3:00 p.m. BST) on May 8, 2026.
• ·Record date for ordinary shares: 6:00 p.m. BST (1:00 p.m. ET) on May 12, 2026.
• ·ADS Record Date: 5:00 p.m. ET on April 9, 2026.
• ·Share allotment authority replaces prior authority from May 22, 2023 AGM.

09-04-2026

C4 Therapeutics, Inc. (Nasdaq: CCCC) entered a new collaboration agreement with Roche to discover and develop degrader-antibody conjugates (DACs) for two undisclosed oncology targets, with an option for a third. C4T will receive a $20 million upfront payment and is eligible for over $1 billion in discovery, development, and commercial milestones, plus tiered royalties on future sales. The deal leverages C4T's TORPEDO platform for degrader payloads and Roche's antibody expertise, building on their decade-long partnership.

• ·Collaboration covers two exclusive oncology targets initially, with Roche option for a third target triggering additional payment
• ·C4T responsible for designing degrader payloads; Roche handles antibody selection, conjugation, preclinical/clinical development, and commercialization
• ·Near-term discovery milestone payments expected across the programs

09-04-2026

Mountain Lake Acquisition Corp. II (MLAC II), a SPAC, and Terra Quantum AG announced on April 9, 2026, a non-binding letter of intent for a business combination valuing Terra Quantum at $3.25 billion. The transaction aims to accelerate commercialization of Terra Quantum's quantum technologies, including algorithms, software, quantum security, and hybrid solutions, while providing access to public markets for growth. Completion remains subject to definitive agreements, due diligence, shareholder and regulatory approvals, with no assurance of closing.

• ·MLAC II securities: MLAAU (Units), MLAA (Class A ordinary shares), MLAAW (Warrants) listed on Nasdaq Stock Market LLC.
• ·MLAC II address: 930 Tahoe Blvd STE 802 PMB 45, Incline Village, NV 89451; phone: (775) 204-1489.
• ·Proposed post-combination listing on public markets; future proxy statement/prospectus to be filed with SEC if definitive agreement reached.

09-04-2026

Orthofix Medical Inc. announced a Spine leadership realignment, eliminating the President, Global Spine Solutions role, with Shaeffer Bannigan, Mark Sienkiewicz, John Winge, and Patrick Fisher assuming expanded responsibilities reporting to CEO Massimo Calafiore to accelerate growth and execution. Preliminary Q1 2026 net sales were $196.7 million (up 1.6% YoY reported, 0.4% constant currency), or $196.4 million pro forma excluding M6 discs (up 3.8% reported, 2.7% constant currency), though impacted by a 94.2% decline in discontinued M6 product lines. The company reaffirmed FY2026 guidance of $850-860 million net sales (5.5% pro forma constant currency growth at midpoint), $95-98 million adjusted EBITDA (70 bps margin expansion), and positive free cash flow.

• ·Q1 2026 earnings call and webcast scheduled for May 5, 2026, at 8:30 am ET.
• ·Participation in 25th Annual Needham Virtual Healthcare Conference on April 14, 2026.

09-04-2026

Treace Medical Concepts announced preliminary unaudited Q1 2026 revenue of $47.0 million to $47.2 million and cash, cash equivalents, and marketable securities of $51.9 million as of March 31, 2026, reflecting a $3.5 million QoQ increase from $48.4 million at December 31, 2025—outperforming the $0.4 million increase in Q1 2025. The company narrowed its FY2026 revenue guidance to $202 million to $212 million from the prior $200 million to $212 million range, driven by case volume growth but offset by product and price mix headwinds in its expanded bunion portfolio. Chief Commercial Officer Gaetano M. Guglielmino departs effective April 8, 2026, amicably, with responsibilities absorbed by existing staff including SVP Sales reporting to CEO John T. Treace; he will consult through January 31, 2027.

• ·Consulting agreement includes COBRA premium payments, pro-rated 2026 target bonus, apartment rent payments until lease assignment, and continued vesting of prior equity awards.
• ·Mr. Guglielmino signed a release of claims and confirmed enforceability of confidentiality, nonsolicitation, and noncompetition agreements.

09-04-2026

Nova Agritech Limited disclosed under SEBI (SAST) Regulation 31(4) and (5) that its promoters—Kiran Kumar Atukuri, Malathi S, Suraksha Agri Retails (India) Pvt Ltd, and Yeluri Family Trust—encumbered no shares during FY 2025-26 ended March 31, 2026. This annual nil disclosure indicates no pledging activity by promoters, avoiding potential liquidity signals.

• ·Filing date: April 09, 2026
• ·FY period: 2025-26 ended March 31, 2026
• ·Regulation: 31(4) and (5) of SEBI (SAST), 2011
• ·Registered office: Sy.No.251/A/1., Singannaguda Village, Mulugu Mandal, Medak, Siddipet - 502279, Telangana, India
• ·CIN: L01119TG2007PLC053901
• ·Scrip Code: 544100; Trading Symbol: NOVAAGRI